These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8953827

  • 1. [Evaluation methodology of viral vaccines].
    Aymard M.
    Therapie; 1996; 51(4):439-43. PubMed ID: 8953827
    [No Abstract] [Full Text] [Related]

  • 2. Overview of current preclinical testing strategies for viral vaccines.
    Wood DJ.
    Dev Biol Stand; 1998; 95():19-23. PubMed ID: 9855410
    [No Abstract] [Full Text] [Related]

  • 3. [Principles of controlled trials (author's transl)].
    Fink H.
    Arzneimittelforschung; 1978; 28(11a):2017-9. PubMed ID: 383091
    [Abstract] [Full Text] [Related]

  • 4. Risks and benefits of vaccinia-vectored vaccine from the regulatory perspective.
    Marcus-Sekura CJ, Quinnan GV.
    Res Virol; 1989; 140(5):467-9; discussion 487-91. PubMed ID: 2685956
    [No Abstract] [Full Text] [Related]

  • 5. Shifting the burden: restructuring the drug review process.
    Scoville B.
    Clin Pharmacol Ther; 1991 Mar; 49(3):229-33. PubMed ID: 2007316
    [No Abstract] [Full Text] [Related]

  • 6. Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
    Epstein BJ.
    Curr Opin Investig Drugs; 2007 Apr; 8(4):331-7. PubMed ID: 17458184
    [Abstract] [Full Text] [Related]

  • 7. MRI for development of disease-modifying osteoarthritis drugs.
    Burstein D.
    NMR Biomed; 2006 Oct; 19(6):669-80. PubMed ID: 16986116
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Drug screening and evaluation. Directions and execution].
    Renovanz HD.
    Fortschr Med; 1977 Mar 10; 95(10):601-2. PubMed ID: 844757
    [No Abstract] [Full Text] [Related]

  • 10. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
    Schimke K, Davis TM.
    Curr Opin Investig Drugs; 2007 Apr 10; 8(4):338-44. PubMed ID: 17458185
    [Abstract] [Full Text] [Related]

  • 11. Non-target effects of live vaccines: myth, reality and demagoguery.
    Levine MM.
    Dev Biol Stand; 1995 Apr 10; 84():33-8. PubMed ID: 7796965
    [No Abstract] [Full Text] [Related]

  • 12. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T.
    Curr Opin Mol Ther; 2004 Aug 10; 6(4):443-50. PubMed ID: 15468603
    [Abstract] [Full Text] [Related]

  • 13. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
    Drew BG, Calkin AC.
    Curr Opin Investig Drugs; 2007 Apr 10; 8(4):324-30. PubMed ID: 17458183
    [Abstract] [Full Text] [Related]

  • 14. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.
    Hay JW, Yu WM.
    Value Health; 2000 Apr 10; 3(3):181-5. PubMed ID: 16464182
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Canada's new guidelines for the economic evaluation of pharmaceuticals.
    Menon D, Schubert F, Torrance GW.
    Med Care; 1996 Dec 10; 34(12 Suppl):DS77-86. PubMed ID: 8969316
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
    Kohberger RC.
    Stat Med; 2009 Jan 15; 28(1):177-8, author reply 178-9. PubMed ID: 18937271
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.